BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.

Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for ...

Scientists have discovered how leukemia cells outsmart a leading treatment and may have found a way to stop them. Scientists ...

Caremark unit delays adding the company's new HIV prevention drug Yeztugo over pricing concerns. Read more here.

The monarchE trial's primary overall survival (OS) analysis presented at ESMO 2025 confirms that 2 years of ...

Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer. Adding immunotherapy to platinum-based chemotherapy is an established standard of care for ...